drugset / Trial / NCT03916744
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.
Timeline
- Start
- 2019-07-26
- Primary completion
- 2021-05-25
- Completion
- 2021-05-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Giredestrant | Small molecule | 10 mg | Oral |
| Subject | Giredestrant | Small molecule | 30 mg | Oral |
| Subject | Giredestrant | Small molecule | 100 mg | Oral |